文献速递腹部介入US

比较Biopince™与Achieve™活检针在实时超声引导下经皮非靶向肝活检中的 adequacy

Adequacy of percutaneous non-targeted liver biopsy under real-time ultrasound guidance when comparing the Biopince™ and Achieve™ biopsy needle.
PubMed 文献 · Br J Radiol · 2017-10-03

本研究回顾性比较了Biopince 16G与Achieve 18G活检针在实时超声引导下经皮非靶向肝活检中的标本 adequacy。Biopince针获得的总核心长度和门管区数量显著大于Achieve针,且 adequacy 率显著提高,无重大并发症。

要点

  • Biopince 16G针的平均总核心长度和门管区数量均显著大于Achieve 18G针。
  • Biopince 16G针的标本 adequacy 率显著高于Achieve 18G针。
  • 使用Biopince 16G针未出现重大并发症。

核心结论

  • 与Achieve 18G针相比,Biopince 16G针可获得显著更大的总核心长度和门管区数量,并显著提高标本 adequacy 率,且无重大并发症。

研究设计与样本

  • 回顾性研究,共纳入194例经皮非靶向肝活检,其中Biopince针53例,Achieve针141例,依据皇家学院(Royal College)病理学家指南评估 adequacy。

诊断标准与关键数值

  • Biopince针 adequacy 率为31.3%(15例),Achieve针为1.3%(1例),p<0.001;Biopince针 compromised 率为66.7%(32例),Achieve针为50.6%(39例);Biopince针 inadequate 率为2%(1例),Achieve针为48.1%(37例)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this study was to compare the adequacy rates of percutaneous liver biopsies, in parenchymal liver disease, using the BiopinceTM (Argon Medical, Texas, TX, ) 16G and AchieveTM (Carefusion, Illinois, IL, USA) 18G biopsy needles in relation to the Royal College of Pathologists guidelines and to assess risk of complications.

METHODS: Data for all percutaneous non-targeted "medical" liver biopsies using the Biopince 16G and Achieve 18G biopsy needles were collected retrospectively over a 2-year period. Total biopsy core length and number of portal tracts was recorded along with adequacy of biopsy as assessed according to Royal College of Pathologists criteria.

RESULTS: In total, 194 percutaneous liver biopsies met the inclusion criteria; 53 using the Biopince needle and 141 using the Achieve needle. The mean total core length was 23 mm (SD 4.1) and 20 mm (SD 6.8) for the Biopince and Achieve needles, respectively (p = 0.0005). The mean number of portal tracts was 11 (SD 4.2) and 7 (SD 3.4) for the Biopince and Achieve needles, respectively (p < 0.0001). An adequate biopsy was obtained in 15 (31.3%) and 1 (1.3%) case using the Biopince and Achieve needles, respectively (p < 0.001). Compromised biopsies were obtained in 32 (66.7%) and 39 (50.6%) cases using the Biopince and Achieve needles, respectively. Inadequate biopsies were obtained in 1 (2%) and 37 (48.1%) cases using the Biopince and Achieve needles, respectively.

CONCLUSION: The Biopince 16G needle, when compared with the Achieve 18G needle, acquires a significantly greater total core length and number of portal tracts with significantly improved adequacy rates. There were no major complications associated with its use. Advances in knowledge: The Biopince 16G needle achieves significantly better specimen adequacy, when compared with the Achieve 18G needle and with no added major complications associated with its use.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Hall TC, Deakin C, Atwal GS, et al. Adequacy of percutaneous non-targeted liver biopsy under real-time ultrasound guidance when comparing the Biopince™ and Achieve™ biopsy needle. Br J Radiol. 2017. PMID: 28972801. doi:10.1259/bjr.20170397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。